#USA #New York #Everest Group #ACTO #Pharmaceutical Technology

ACTO: A Leader in Pharmaceutical Technology

In a crucial development for the life sciences industry, ACTO has proudly announced its inclusion in the Everest Group's Top 50™ Pharmaceutical Technology Providers for 2026. This recognition underscores ACTO’s commitment to merging human intelligence with empathetic AI, a crucial combination for driving advancements in life sciences technology.

Significance of the Recognition

The inclusion in this prestigious list emphasizes ACTO's leadership in AI-enabled field excellence, utilizing agent-based AI tailor-made for the pharmaceutical sector. The Everest Group's study provides an objective overview of the pharmaceutical technology landscape, highlighting critical trends such as agent-based AI, cloud-native capabilities, and strategic partnerships that are reshaping the industry.

“Pharma companies are increasingly investing in technologies that enhance commercial and medical execution,” shares Durga Ambati, Vice President at the Everest Group. This shift towards omnichannel capabilities and coherent customer data unification reflects a mounting demand for AI-powered personalization strategies during the engagement of healthcare professionals and stakeholders.

The Evolving Role of AI in Pharma

As the pharmaceutical landscape transitions from isolated workflows to interconnected, AI-driven processes, there is a heightened focus on technology platforms that seamlessly integrate fragmented data and systems while ensuring governance, traceability, and compliance, especially in regulated environments. ACTO stands out as a leader through sustained investments in AI across various facets, including knowledge support, simulated coaching, and agent-based workflow automation.

The recognition also coincides with a significant shift towards agent-based AI that moves beyond mere